News headlines about Bio-Rad Laboratories (NYSE:BIO) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 48.1124367948482 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Bio-Rad Laboratories (NYSE:BIO) opened at 215.44 on Friday. Bio-Rad Laboratories has a one year low of $154.70 and a one year high of $242.79. The firm has a market capitalization of $6.38 billion, a price-to-earnings ratio of 425.77 and a beta of 0.93. The stock has a 50 day moving average of $223.50 and a 200 day moving average of $216.04.

Several equities analysts have recently commented on BIO shares. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective on the stock. TheStreet lowered shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Jefferies Group LLC restated a “buy” rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Finally, Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $228.80.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/09/08/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-bio-rad-laboratories-bio-share-price.html.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.29% of the stock is owned by corporate insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Insider Buying and Selling by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.